2026-10-30 01:43:47
Dasatinib is a second-generation oral tyrosine kinase inhibitor for Philadelphia chromosome-positive CML and selected Ph+ ALL, requiring blood count, molecular response, and cardiopulmonary monitoring.
2026-10-29 04:29:10
Eltrombopag raises platelet counts by stimulating megakaryocyte production, used in selected ITP and severe aplastic anemia. Management requires liver monitoring, thrombosis vigilance, and cation-aware dosing.
2026-10-23 05:40:09
Explain the reasons why Parkitinib cannot be used in combination with potent CYP3A4 drugs, as well as the caution and medical signals for patients with bleeding, QT prolongation, and severe infections.
2026-10-22 07:20:42
Pomalidomide is used for multiple myeloma and Kaposi sarcoma and can cause blood cell reductions, infection, and blood clots. This article outlines common side effects, serious warning signs, monitoring, and special precautions.
2026-10-22 07:14:59
Dasatinib is a targeted therapy for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and some cases of Ph+ acute lymphoblastic leukemia (Ph+ ALL). This article outlines adult and pediatric starting doses, how to take the medicine, drug interactions, and long-term monitoring.
2026-10-22 07:01:57
Acalabrutinib alone can control chronic lymphocytic leukemia in many patients, but remission is not the same as a cure. This article explains how it works, why treatment often continues long term, and what options remain if it stops working.
2026-10-21 03:20:56
Ibrutinib resistance does not mean self-escalating dose. Separate true disease progression from toxicity; CLL/SLL may move to venetoclax or non-covalent BTK, MCL may use pirtobrutinib or CAR-T based on prior lines and genomic testing.
2026-10-21 03:08:13
Quizartinib is for adults with newly diagnosed FLT3-ITD-positive AML confirmed by an authorized test; used with cytarabine plus anthracycline induction, cytarabine consolidation, and single-agent maintenance. Not for FLT3-TKD only or post-allo-HSCT maintenance; QT prolongation requires ECG monitoring.
2026-10-21 02:43:10
Ibrutinib is used in adults with previously treated mantle cell lymphoma by blocking BTK signaling, but it does not guarantee cure. Monitor bleeding, infection, cytopenias, arrhythmia, and drug interactions; after progression consider non-covalent BTK inhibitors or CAR-T.
2026-10-14 04:40:08
This article reviews the mechanism, indications, dosing, toxicity management, and global clinical data of Selinexor, providing an objective reference for RRMM patients.
2026-10-13 07:01:50
Acalabrutinib is a selective BTK inhibitor that covalently blocks the BTK active-site cysteine and interrupts BCR downstream signaling in CLL/SLL and related B-cell tumors. It affects malignant and normal B cells, so infection, bleeding, arrhythmia, cytopenias, and resistance pathways all require structured monitoring.
2026-10-13 06:58:10
Bosutinib is an oral BCR-ABL and SRC-family tyrosine kinase inhibitor for newly diagnosed or resistant/intolerant Philadelphia chromosome-positive chronic-phase CML in adults, resistant/intolerant accelerated or blast-phase CML in adults, and chronic-phase CML in children aged 1 year and older. Main safety work covers diarrhea, liver injury, myelosuppression, and fluid retention.